Literature DB >> 30689161

HBsAg-negative/anti-HBc-positive patients treated with rituximab: prophylaxis or monitoring to prevent hepatitis B reactivation?

Linda Drößler1, Clara Lehmann1,2,3, Karin Töpelt1, Dirk Nierhoff4, Jörg J Vehreschild1,2, Jan Rybniker1,2,3, Michael Hallek1, Julia Fischer1, Verena Stormberg5, Gerd Fätkenheuer1,2, Ulrike Wieland6, Norma Jung7.   

Abstract

Rituximab (RTX) has been classified as a drug associated with a high risk for hepatitis B virus (HBV) reactivation in HbsAg-negative/anti-HBc-positive patients. However, data on frequency of HBV reactivation are limited especially for RTX monotherapy. Several new recommendations for screening, monitoring and prophylactic antiviral treatment have been published recently. Here, we report the real-life experience in the management and reactivation rate of HbsAg-negative/anti-HBc-positive patients treated with RTX with or without chemotherapy from a large cohort and discuss our results in the light of updated recommendations.

Entities:  

Keywords:  Autoimmune diseases; Hematologic diseases; Hepatitis B; Monotherapy; Reactivation; Risk groups; Rituximab

Mesh：

Substances：

Year:  2019        PMID： 30689161     DOI： 10.1007/s15010-019-01271-z

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


  11 in total

Review 1.  Management of patients with hepatitis B who require immunosuppressive therapy.

Authors:  Jessica P Hwang; Anna S-F Lok
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-11-19       Impact factor: 46.802

2.  FDA: Increased HBV reactivation risk with ofatumumab or rituximab.

Authors:  Mike Mitka
Journal:  JAMA       Date:  2013-10-23       Impact factor: 56.272

Review 3.  American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.

Authors:  K Rajender Reddy; Kimberly L Beavers; Sarah P Hammond; Joseph K Lim; Yngve T Falck-Ytter
Journal:  Gastroenterology       Date:  2014-10-31       Impact factor: 22.682

Review 4.  American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.

Authors:  Robert P Perrillo; Robert Gish; Yngve T Falck-Ytter
Journal:  Gastroenterology       Date:  2014-10-31       Impact factor: 22.682

5.  Preventing hepatitis B reactivation due to immunosuppressive drug treatments.

Authors:  Robert P Perrillo; Paul Martin; Anna S Lok
Journal:  JAMA       Date:  2015-04-28       Impact factor: 56.272

6.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.

Authors: 
Journal:  J Hepatol       Date:  2017-04-18       Impact factor: 25.083

Review 7.  Hepatitis B Virus Reactivation in the Setting of Cancer Chemotherapy and Other Immunosuppressive Drug Therapy.

Authors:  Stevan A Gonzalez; Robert P Perrillo
Journal:  Clin Infect Dis       Date:  2016-06-01       Impact factor: 9.079

8.  AASLD guidelines for treatment of chronic hepatitis B.

Authors:  Norah A Terrault; Natalie H Bzowej; Kyong-Mi Chang; Jessica P Hwang; Maureen M Jonas; M Hassan Murad
Journal:  Hepatology       Date:  2015-11-13       Impact factor: 17.425

9.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.

Authors:  S K Sarin; M Kumar; G K Lau; Z Abbas; H L Y Chan; C J Chen; D S Chen; H L Chen; P J Chen; R N Chien; A K Dokmeci; Ed Gane; J L Hou; W Jafri; J Jia; J H Kim; C L Lai; H C Lee; S G Lim; C J Liu; S Locarnini; M Al Mahtab; R Mohamed; M Omata; J Park; T Piratvisuth; B C Sharma; J Sollano; F S Wang; L Wei; M F Yuen; S S Zheng; J H Kao
Journal:  Hepatol Int       Date:  2015-11-13       Impact factor: 6.047

Review 10.  Prevention of Hepatitis B reactivation in the setting of immunosuppression.

Authors:  Venessa Pattullo
Journal:  Clin Mol Hepatol       Date:  2016-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.